MPERIA -THE CD36 THERAPEUTICS DEVELOPMENT COMPANY

Sustained leadership position for clinical development of therapeutics for CD36-mediated diseases.

hero-ind-ls-biotech-vials-001.jpg

CD36-A NOVEL TARGET

In the last decade CD36 receptor research has transitioned into a weekly-cited, critical-path intermediary in the progression of several major diseases, including:

 

WORLD-CLASS BOARDS & MGMT

Co-founder & CSO, Universite de Montreal

Leroux.png

CAB Chair, Drug Delivery,
ETH, Zurich

Weber.jpg

Cardiovascular, Klinikum Universitat Munchen

DSaban.png

Ophthalmology, Duke University

Voros.png

Cardiovascular, Global Genomics Group, NYC

JDunaief.png

Ophthalmology,

Scheie Eye Institute,

University of Pennsylvania

KMcBride.png

 

BOD, Amorchem, Montreal

VB.png

COO,

Mperia Therapeutics Inc

 

CD36 MODULATES MACROPHAGES

Mperia's team have spent >20 years understanding the CD36 receptor and have developed highly selective CD36-receptor mediated ligands to re-program M1 macrophages from a pro- to anti-inflammatory action.
 

 

 

 

MEDCHEM PIPELINE

We have carefully developed and tested a series of potent, short-chain peptides for high specificity binding of the CD36 receptor, to promote the best therapeutic of all, the patient’s own innate immune system.


The confirmed mechanism-of-action promotes macrophage rebalancing to an anti-inflammatory action. Leading clinical programs are described below:

 

MEDIA